Optimism that Greece and its creditors were close to finalizing a deal sent the markets soaring during the midday with the Dow climbing 105 points to 18,121. Nasdaq gained 32 points to 5,149.

On the upside

Epizyme (Nasdaq: EPZM) reported positive results from an ongoing Phase 1 study of tazemetostat to treat patients with advanced B-cell non-Hodgkin lymphomas and solid tumors.

JMP Securities initiated coverage of Akebia Therapeutics (Nasdaq: AKBA) with a Market Outperform rating.

Transgenomic (Nasdaq: TBIO) will launch up to six new genetic cancer tests this year.
 
On the downside

William Blair downgraded Polycom (Nasdaq: PLCM) from a Market Perform rating to an Underperform rating.

Profit taking continued to weigh down shares of Synergy Pharmaceuticals (Nasdaq: SGYP).

Shares of FuelCell Energy (Nasdaq: FCEL) extended its losses.
 
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 3 on the NYSE and by more than 5 to 3 on Nasdaq. The broader S&P 500 gained 12 points to 2122. Bitcoin rose $3 to $246.